Therapeutic effects of crizotinib in EML4-ALK-positive patients with non-small-cell lung cancer / 南方医科大学学报
Journal of Southern Medical University
;
(12): 753-757, 2015.
Article
in Chinese
| WPRIM
| ID: wpr-355289
ABSTRACT
<p><b>OBJEVTIVE</b>To evaluate the therapeutic effects of different therapeutic regimens for non-small-cell lung cancer (NSCLC) with or without EML4-ALK rearrangement.</p><p><b>METHODS</b>Twenty-one ALK-positive and 50 ALK-negative NSCLC patients who received voluntarily EML4-ALK testing and 75 NSCLC patients without AL testing were enrolled in this study. The 3 groups of patients received different treatments, and the therapeutic effects, progression-free survival (PFS), and treatment-related adverse events were analyzed.</p><p><b>RESULTS</b>Crizotinib treatment obviously prolonged the PFS in EML4-ALK-positive patients with an objective response rate (OOR) of 61.9% and a median response duration of 16 months, which were significantly better than those in with ALK-negative patients and patients without ALK testing who received different second-line therapies.</p><p><b>CONCLUSION</b>Crizotinib is superior to platinum-based chemotherapy in NSCLC patients with ALK rearrangement. ALK rearrangement id not a modifier of the effect of chemotherapy regimens in NSCLC patients.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pyrazoles
/
Pyridines
/
Oncogene Proteins, Fusion
/
Carcinoma, Non-Small-Cell Lung
/
Disease-Free Survival
/
Therapeutic Uses
/
Drug Therapy
/
Lung Neoplasms
Limits:
Humans
Language:
Chinese
Journal:
Journal of Southern Medical University
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS